Stem definition | Drug id | CAS RN |
---|---|---|
56 | 59-66-5 |
Dose | Unit | Route |
---|---|---|
0.75 | g | O |
0.75 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.64 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 90 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 75.14 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.37 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.65 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.04 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 13 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 27, 1953 | FDA | TEVA BRANDED PHARM |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Angle closure glaucoma | 153.93 | 17.40 | 39 | 6925 | 1995 | 50596165 |
Idiopathic intracranial hypertension | 148.35 | 17.40 | 39 | 6925 | 2310 | 50595850 |
Hair follicle tumour benign | 128.89 | 17.40 | 25 | 6939 | 362 | 50597798 |
Metabolic acidosis | 118.33 | 17.40 | 71 | 6893 | 38754 | 50559406 |
Papilloedema | 111.56 | 17.40 | 34 | 6930 | 3439 | 50594721 |
Intraocular pressure increased | 99.93 | 17.40 | 35 | 6929 | 5481 | 50592679 |
Choroidal effusion | 95.47 | 17.40 | 20 | 6944 | 434 | 50597726 |
Intracranial pressure increased | 84.84 | 17.40 | 29 | 6935 | 4223 | 50593937 |
Off label use | 76.15 | 17.40 | 187 | 6777 | 474239 | 50123921 |
Choroidal detachment | 67.42 | 17.40 | 13 | 6951 | 182 | 50597978 |
Complications of bone marrow transplant | 56.13 | 17.40 | 13 | 6951 | 453 | 50597707 |
Hepatosplenic T-cell lymphoma | 53.12 | 17.40 | 13 | 6951 | 575 | 50597585 |
Macular detachment | 44.24 | 17.40 | 8 | 6956 | 77 | 50598083 |
Retinal detachment | 41.03 | 17.40 | 18 | 6946 | 5111 | 50593049 |
Flat anterior chamber of eye | 40.21 | 17.40 | 7 | 6957 | 53 | 50598107 |
Intellectual disability | 39.85 | 17.40 | 11 | 6953 | 783 | 50597377 |
Hypercapnia | 39.49 | 17.40 | 17 | 6947 | 4610 | 50593550 |
Aggression | 38.38 | 17.40 | 28 | 6936 | 21088 | 50577072 |
Corneal oedema | 37.89 | 17.40 | 12 | 6952 | 1375 | 50596785 |
Acute generalised exanthematous pustulosis | 37.03 | 17.40 | 20 | 6944 | 8918 | 50589242 |
Visual impairment | 36.56 | 17.40 | 46 | 6918 | 68229 | 50529931 |
Glaucoma | 36.00 | 17.40 | 24 | 6940 | 15662 | 50582498 |
Photophobia | 34.70 | 17.40 | 23 | 6941 | 14864 | 50583296 |
Hypotony of eye | 34.00 | 17.40 | 7 | 6957 | 139 | 50598021 |
Ophthalmic vein thrombosis | 33.58 | 17.40 | 7 | 6957 | 148 | 50598012 |
Lens dislocation | 31.62 | 17.40 | 5 | 6959 | 19 | 50598141 |
Visual field defect | 29.87 | 17.40 | 15 | 6949 | 5764 | 50592396 |
Myopia | 28.93 | 17.40 | 10 | 6954 | 1503 | 50596657 |
Cerebral venous sinus thrombosis | 27.98 | 17.40 | 10 | 6954 | 1658 | 50596502 |
Persecutory delusion | 27.96 | 17.40 | 11 | 6953 | 2376 | 50595784 |
Psychiatric decompensation | 26.74 | 17.40 | 9 | 6955 | 1249 | 50596911 |
Retinopathy haemorrhagic | 26.56 | 17.40 | 4 | 6960 | 10 | 50598150 |
Dysphoria | 26.47 | 17.40 | 13 | 6951 | 4761 | 50593399 |
Myasthenic syndrome | 26.28 | 17.40 | 6 | 6958 | 196 | 50597964 |
Product contamination microbial | 26.05 | 17.40 | 6 | 6958 | 204 | 50597956 |
Iridocyclitis | 25.97 | 17.40 | 10 | 6954 | 2039 | 50596121 |
Haemorrhagic diathesis | 25.69 | 17.40 | 12 | 6952 | 3936 | 50594224 |
Vision blurred | 24.50 | 17.40 | 41 | 6923 | 78606 | 50519554 |
Retroperitoneal oedema | 24.24 | 17.40 | 4 | 6960 | 21 | 50598139 |
Toxic leukoencephalopathy | 23.69 | 17.40 | 7 | 6957 | 636 | 50597524 |
Appetite disorder | 23.44 | 17.40 | 13 | 6951 | 6101 | 50592059 |
Ocular pemphigoid | 23.13 | 17.40 | 4 | 6960 | 29 | 50598131 |
CSF pressure increased | 23.07 | 17.40 | 5 | 6959 | 128 | 50598032 |
Cross sensitivity reaction | 22.80 | 17.40 | 9 | 6955 | 1960 | 50596200 |
Transmission of an infectious agent via product | 22.68 | 17.40 | 5 | 6959 | 139 | 50598021 |
Ocular surface disease | 22.57 | 17.40 | 4 | 6960 | 34 | 50598126 |
Optic disc haemorrhage | 22.07 | 17.40 | 4 | 6960 | 39 | 50598121 |
Product use in unapproved indication | 22.05 | 17.40 | 49 | 6915 | 115770 | 50482390 |
Drug ineffective | 21.81 | 17.40 | 189 | 6775 | 819144 | 49779016 |
Arthritis infective | 21.79 | 17.40 | 12 | 6952 | 5557 | 50592603 |
Acute respiratory failure | 21.45 | 17.40 | 23 | 6941 | 28759 | 50569401 |
Sickle cell anaemia with crisis | 21.18 | 17.40 | 11 | 6953 | 4532 | 50593628 |
Diplopia | 21.09 | 17.40 | 19 | 6945 | 19241 | 50578919 |
Lactic acidosis | 20.32 | 17.40 | 24 | 6940 | 33331 | 50564829 |
Acidosis | 19.58 | 17.40 | 14 | 6950 | 10213 | 50587947 |
Meningitis aseptic | 19.20 | 17.40 | 10 | 6954 | 4142 | 50594018 |
Conjunctival hyperaemia | 18.93 | 17.40 | 8 | 6956 | 2074 | 50596086 |
Foetal exposure during pregnancy | 18.88 | 17.40 | 21 | 6943 | 27338 | 50570822 |
Vitreous disorder | 18.78 | 17.40 | 4 | 6960 | 94 | 50598066 |
Dropped head syndrome | 18.36 | 17.40 | 4 | 6960 | 105 | 50598055 |
Splenomegaly | 17.98 | 17.40 | 13 | 6951 | 9647 | 50588513 |
Skin warm | 17.97 | 17.40 | 10 | 6954 | 4725 | 50593435 |
Retinal vascular occlusion | 17.88 | 17.40 | 5 | 6959 | 373 | 50597787 |
Nasal flaring | 17.70 | 17.40 | 3 | 6961 | 19 | 50598141 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intraocular pressure increased | 159.59 | 21.07 | 46 | 3269 | 4743 | 29566469 |
Choroidal detachment | 128.98 | 21.07 | 24 | 3291 | 343 | 29570869 |
Metabolic acidosis | 109.32 | 21.07 | 62 | 3253 | 37600 | 29533612 |
Angle closure glaucoma | 98.55 | 21.07 | 22 | 3293 | 803 | 29570409 |
Choroidal effusion | 86.66 | 21.07 | 15 | 3300 | 138 | 29571074 |
Toxic epidermal necrolysis | 63.93 | 21.07 | 34 | 3281 | 18119 | 29553093 |
Congenital emphysema | 48.58 | 21.07 | 6 | 3309 | 0 | 29571212 |
Ocular surface disease | 42.65 | 21.07 | 7 | 3308 | 45 | 29571167 |
Visual acuity reduced | 41.75 | 21.07 | 24 | 3291 | 14852 | 29556360 |
Hyphaema | 37.00 | 21.07 | 9 | 3306 | 479 | 29570733 |
Glaucoma | 35.79 | 21.07 | 16 | 3299 | 5841 | 29565371 |
Drug ineffective | 31.12 | 21.07 | 100 | 3215 | 363070 | 29208142 |
Hypochloraemia | 31.10 | 21.07 | 8 | 3307 | 535 | 29570677 |
Burkholderia test positive | 30.60 | 21.07 | 9 | 3306 | 990 | 29570222 |
Corneal oedema | 29.42 | 21.07 | 9 | 3306 | 1133 | 29570079 |
Acidosis hyperchloraemic | 28.93 | 21.07 | 7 | 3308 | 364 | 29570848 |
Photocoagulation | 27.99 | 21.07 | 4 | 3311 | 8 | 29571204 |
Drug reaction with eosinophilia and systemic symptoms | 26.01 | 21.07 | 23 | 3292 | 27969 | 29543243 |
Trabeculectomy | 25.57 | 21.07 | 4 | 3311 | 18 | 29571194 |
Product contamination microbial | 25.47 | 21.07 | 7 | 3308 | 604 | 29570608 |
Off label use | 24.05 | 21.07 | 81 | 3234 | 300719 | 29270493 |
Dysmetria | 23.40 | 21.07 | 6 | 3309 | 396 | 29570816 |
Crystalluria | 23.21 | 21.07 | 6 | 3309 | 409 | 29570803 |
Hypocapnia | 22.90 | 21.07 | 5 | 3310 | 164 | 29571048 |
Transmission of an infectious agent via product | 22.62 | 21.07 | 5 | 3310 | 174 | 29571038 |
Hypercapnia | 22.19 | 21.07 | 10 | 3305 | 3716 | 29567496 |
Visual acuity tests abnormal | 21.98 | 21.07 | 4 | 3311 | 50 | 29571162 |
Corneal opacity | 21.95 | 21.07 | 6 | 3309 | 507 | 29570705 |
Endophthalmitis | 21.38 | 21.07 | 9 | 3306 | 2839 | 29568373 |
Intraocular pressure decreased | 21.12 | 21.07 | 4 | 3311 | 63 | 29571149 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Angle closure glaucoma | 243.58 | 15.92 | 60 | 9274 | 2597 | 64486801 |
Intraocular pressure increased | 203.85 | 15.92 | 67 | 9267 | 8235 | 64481163 |
Choroidal detachment | 203.31 | 15.92 | 39 | 9295 | 503 | 64488895 |
Choroidal effusion | 168.46 | 15.92 | 34 | 9300 | 578 | 64488820 |
Metabolic acidosis | 142.90 | 15.92 | 102 | 9232 | 70856 | 64418542 |
Hair follicle tumour benign | 130.71 | 15.92 | 26 | 9308 | 409 | 64488989 |
Idiopathic intracranial hypertension | 128.74 | 15.92 | 36 | 9298 | 2557 | 64486841 |
Off label use | 88.96 | 15.92 | 245 | 9089 | 632561 | 63856837 |
Papilloedema | 87.03 | 15.92 | 32 | 9302 | 5473 | 64483925 |
Intracranial pressure increased | 83.08 | 15.92 | 33 | 9301 | 6956 | 64482442 |
Ocular surface disease | 62.55 | 15.92 | 11 | 9323 | 84 | 64489314 |
Hypercapnia | 60.24 | 15.92 | 27 | 9307 | 7667 | 64481731 |
Corneal oedema | 57.85 | 15.92 | 19 | 9315 | 2324 | 64487074 |
Glaucoma | 53.76 | 15.92 | 32 | 9302 | 16316 | 64473082 |
Complications of bone marrow transplant | 51.48 | 15.92 | 13 | 9321 | 622 | 64488776 |
Toxic epidermal necrolysis | 49.77 | 15.92 | 42 | 9292 | 37124 | 64452274 |
Transmission of an infectious agent via product | 49.10 | 15.92 | 10 | 9324 | 178 | 64489220 |
Hepatosplenic T-cell lymphoma | 48.15 | 15.92 | 13 | 9321 | 809 | 64488589 |
Product contamination microbial | 47.23 | 15.92 | 13 | 9321 | 870 | 64488528 |
Hyphaema | 46.19 | 15.92 | 12 | 9322 | 643 | 64488755 |
Photophobia | 44.59 | 15.92 | 29 | 9305 | 17264 | 64472134 |
Macular detachment | 43.06 | 15.92 | 9 | 9325 | 183 | 64489215 |
Visual impairment | 42.52 | 15.92 | 53 | 9281 | 74024 | 64415374 |
Drug ineffective | 41.46 | 15.92 | 234 | 9100 | 840013 | 63649385 |
Retinal detachment | 41.10 | 15.92 | 21 | 9313 | 7955 | 64481443 |
Visual acuity reduced | 39.10 | 15.92 | 32 | 9302 | 27109 | 64462289 |
Flat anterior chamber of eye | 38.84 | 15.92 | 8 | 9326 | 151 | 64489247 |
Vision blurred | 37.20 | 15.92 | 55 | 9279 | 90261 | 64399137 |
Ophthalmic vein thrombosis | 36.51 | 15.92 | 8 | 9326 | 205 | 64489193 |
Myopia | 34.51 | 15.92 | 12 | 9322 | 1746 | 64487652 |
Endophthalmitis | 33.20 | 15.92 | 16 | 9318 | 5349 | 64484049 |
Acidosis hyperchloraemic | 31.59 | 15.92 | 9 | 9325 | 683 | 64488715 |
Hypotony of eye | 30.36 | 15.92 | 7 | 9327 | 227 | 64489171 |
Cerebral venous sinus thrombosis | 30.12 | 15.92 | 11 | 9323 | 1844 | 64487554 |
Acidosis | 29.96 | 15.92 | 23 | 9311 | 17772 | 64471626 |
Visual field defect | 29.56 | 15.92 | 17 | 9317 | 8129 | 64481269 |
Corneal opacity | 29.21 | 15.92 | 9 | 9325 | 896 | 64488502 |
Acute generalised exanthematous pustulosis | 27.76 | 15.92 | 20 | 9314 | 14038 | 64475360 |
Trabeculectomy | 27.32 | 15.92 | 5 | 9329 | 49 | 64489349 |
Photocoagulation | 26.36 | 15.92 | 4 | 9330 | 10 | 64489388 |
Iridocyclitis | 24.84 | 15.92 | 11 | 9323 | 3034 | 64486364 |
Retinal vascular occlusion | 24.75 | 15.92 | 7 | 9327 | 517 | 64488881 |
Vitreous disorder | 24.70 | 15.92 | 6 | 9328 | 244 | 64489154 |
Intellectual disability | 24.17 | 15.92 | 8 | 9326 | 1002 | 64488396 |
Retroperitoneal oedema | 24.04 | 15.92 | 4 | 9330 | 21 | 64489377 |
Dysphoria | 23.91 | 15.92 | 12 | 9322 | 4376 | 64485022 |
Diplopia | 23.67 | 15.92 | 24 | 9310 | 26741 | 64462657 |
Lens dislocation | 22.75 | 15.92 | 5 | 9329 | 130 | 64489268 |
Appetite disorder | 22.16 | 15.92 | 13 | 9321 | 6448 | 64482950 |
Multiple-drug resistance | 22.08 | 15.92 | 13 | 9321 | 6489 | 64482909 |
Blindness | 21.80 | 15.92 | 21 | 9313 | 21998 | 64467400 |
Somnolence | 20.99 | 15.92 | 71 | 9263 | 203574 | 64285824 |
Meningitis aseptic | 20.90 | 15.92 | 12 | 9322 | 5718 | 64483680 |
Psychiatric decompensation | 20.42 | 15.92 | 9 | 9325 | 2454 | 64486944 |
CSF pressure increased | 20.25 | 15.92 | 5 | 9329 | 218 | 64489180 |
Retinopathy haemorrhagic | 20.22 | 15.92 | 4 | 9330 | 61 | 64489337 |
Drug resistance | 19.94 | 15.92 | 25 | 9309 | 35077 | 64454321 |
Burkholderia test positive | 19.71 | 15.92 | 6 | 9328 | 573 | 64488825 |
Myasthenic syndrome | 19.08 | 15.92 | 6 | 9328 | 639 | 64488759 |
Sickle cell anaemia with crisis | 19.01 | 15.92 | 11 | 9323 | 5321 | 64484077 |
Aggression | 18.80 | 15.92 | 28 | 9306 | 46204 | 64443194 |
Optic disc haemorrhage | 18.79 | 15.92 | 4 | 9330 | 89 | 64489309 |
Eye pain | 18.73 | 15.92 | 23 | 9311 | 31602 | 64457796 |
Intraventricular haemorrhage | 18.72 | 15.92 | 10 | 9324 | 4143 | 64485255 |
Persecutory delusion | 18.71 | 15.92 | 10 | 9324 | 4148 | 64485250 |
Prostaglandin analogue periorbitopathy | 18.70 | 15.92 | 3 | 9331 | 12 | 64489386 |
Haemorrhagic diathesis | 18.66 | 15.92 | 11 | 9323 | 5503 | 64483895 |
Arthritis infective | 18.64 | 15.92 | 12 | 9322 | 7018 | 64482380 |
Acute respiratory failure | 18.55 | 15.92 | 29 | 9305 | 49905 | 64439493 |
Visual acuity tests abnormal | 17.71 | 15.92 | 4 | 9330 | 118 | 64489280 |
Product use in unapproved indication | 17.69 | 15.92 | 61 | 9273 | 176557 | 64312841 |
Brain stem haematoma | 17.68 | 15.92 | 4 | 9330 | 119 | 64489279 |
Crystalluria | 17.53 | 15.92 | 6 | 9328 | 832 | 64488566 |
Punctate keratitis | 17.35 | 15.92 | 6 | 9328 | 859 | 64488539 |
Dysmetria | 17.14 | 15.92 | 6 | 9328 | 890 | 64488508 |
Drug reaction with eosinophilia and systemic symptoms | 16.78 | 15.92 | 29 | 9305 | 54188 | 64435210 |
Respiratory alkalosis | 16.50 | 15.92 | 9 | 9325 | 3888 | 64485510 |
Conjunctival hyperaemia | 16.49 | 15.92 | 9 | 9325 | 3890 | 64485508 |
Hyperventilation | 16.48 | 15.92 | 11 | 9323 | 6829 | 64482569 |
Pupillary block | 16.43 | 15.92 | 3 | 9331 | 29 | 64489369 |
None
Source | Code | Description |
---|---|---|
ATC | S01EC01 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Carbonic anhydrase inhibitors |
FDA CS | M0020790 | Sulfonamides |
FDA MoA | N0000000235 | Carbonic Anhydrase Inhibitors |
FDA EPC | N0000175517 | Carbonic Anhydrase Inhibitor |
MeSH PA | D000927 | Anticonvulsants |
MeSH PA | D002257 | Carbonic Anhydrase Inhibitors |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004232 | Diuretics |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D045283 | Natriuretic Agents |
CHEBI has role | CHEBI:23018 | EC 4.2.1.1 inhibitor |
CHEBI has role | CHEBI:35498 | diuretics |
CHEBI has role | CHEBI:35623 | anticonvulsants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Malignant glaucoma | indication | 10100008 | |
Anoxia due to high altitude | indication | 42883007 | |
Absence seizure | indication | 79631006 | |
Open-angle glaucoma | indication | 84494001 | DOID:1067 |
Secondary glaucoma | indication | 95717004 | |
Edema | indication | 267038008 | |
Peripheral edema | indication | 271809000 | |
Angle-closure glaucoma | indication | 392291006 | DOID:13550 |
Peripheral Edema due to Chronic Heart Failure | indication | ||
Metabolic alkalosis | off-label use | 1388004 | |
Myoclonic seizure | off-label use | 37356005 | |
Idiopathic intracranial hypertension | off-label use | 68267002 | DOID:11459 |
Benign intracranial hypertension | off-label use | 68267002 | DOID:11459 |
Familial hypokalemic periodic paralysis | off-label use | 82732003 | DOID:14452 |
Epilepsy | off-label use | 84757009 | DOID:1826 |
Obstructive hydrocephalus | off-label use | 230746009 | DOID:14159 |
Familial periodic paralysis | off-label use | 267607008 | DOID:1029 |
Tonic-clonic epilepsy | off-label use | 352818000 | DOID:7725 |
Simple partial seizure | off-label use | 117891000119100 | |
Urine Alkalinization | off-label use | ||
Hydrocephalus due to Intraventricular Hemorrhage | off-label use | ||
Mixed Epilepsy | off-label use | ||
Renal tubular acidosis | contraindication | 1776003 | DOID:14219 |
Respiratory acidosis | contraindication | 12326000 | |
Hyperkalemia | contraindication | 14140009 | |
Metabolic acidosis, normal anion gap, acidifying salts | contraindication | 18104000 | |
Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Decreased respiratory function | contraindication | 80954004 | |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Disorder of electrolytes | contraindication | 237840007 | |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Recurrent Calcium Renal Calculi | contraindication |
Species | Use | Relation |
---|---|---|
Dogs | Mild congestive heart failure | Indication |
Dogs | Rapid reduction of intraocular pressure | Indication |
Product | Applicant | Ingredients |
---|---|---|
Vetamox Soluble Powder | Zoetis Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.04 | acidic |
pKa2 | 9.21 | acidic |
pKa3 | 1.84 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Carbonic anhydrase 12 | Enzyme | INHIBITOR | Ki | 8.60 | CHEMBL | CHEMBL | |||
Carbonic anhydrase 1 | Enzyme | INHIBITOR | Ki | 7.92 | CHEMBL | CHEMBL | |||
Carbonic anhydrase 4 | Enzyme | INHIBITOR | Ki | 7.96 | CHEMBL | CHEMBL | |||
Carbonic anhydrase 2 | Enzyme | INHIBITOR | Ki | 8.48 | CHEMBL | CHEMBL | |||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 7.22 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 7.27 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 8.60 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 8.51 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 7.96 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 7.39 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 8.24 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 9.10 | CHEMBL | |||||
Carbonic anhydrase V | Enzyme | Ki | 8.74 | CHEMBL | |||||
Carbonic anhydrase-related protein 11 | Enzyme | Ki | 8.24 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 8.05 | CHEMBL | |||||
Aquaporin-1 | Transporter | WOMBAT-PK | |||||||
Carbonic anhydrase | Enzyme | Ki | 7.70 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 7.77 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 7.15 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 7.80 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.22 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 4.92 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 7.14 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.09 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.40 | CHEMBL | |||||
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase | Enzyme | Ki | 7.92 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.96 | CHEMBL | |||||
Alpha carbonic anhydrase | Enzyme | Ki | 7.80 | CHEMBL | |||||
Endochitinase | Enzyme | Ki | 4.68 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.13 | CHEMBL | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 8 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 5.24 | CHEMBL | |||||
Astrosclerin-3 | Enzyme | Ki | 7.29 | CHEMBL | |||||
Beta-carbonic anhydrase 1 | Enzyme | Ki | 6.60 | CHEMBL | |||||
Delta carbonic anhydrase | Unclassified | Ki | 7.08 | CHEMBL | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 8.05 | CHEMBL | |||||
Carbonic anhydrase 2 | Enzyme | IC50 | 6.02 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | IC50 | 7.80 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.57 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 4.08 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.56 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.12 | CHEMBL | |||||
Carbonic anhydrase, alpha family | Unclassified | Ki | 8.37 | CHEMBL | |||||
Carbonate dehydratase | Enzyme | Ki | 8.35 | CHEMBL | |||||
Carbonic anhydrase 2, isoform A; LD26647p | Enzyme | Ki | 7.11 | CHEMBL | |||||
Carbonic anhydrase 1; GH09688p | Enzyme | Ki | 6.97 | CHEMBL |
ID | Source |
---|---|
4017898 | VUID |
N0000146250 | NUI |
D00218 | KEGG_DRUG |
1424-27-7 | SECONDARY_CAS_RN |
167 | RXNORM |
C0000981 | UMLSCUI |
CHEBI:27690 | CHEBI |
AZM | PDB_CHEM_ID |
CHEMBL20 | ChEMBL_ID |
DB00819 | DRUGBANK_ID |
CHEMBL1200814 | ChEMBL_ID |
D000086 | MESH_DESCRIPTOR_UI |
1986 | PUBCHEM_CID |
481 | INN_ID |
6792 | IUPHAR_LIGAND_ID |
O3FX965V0I | UNII |
2596 | MMSL |
4121 | MMSL |
814 | MMSL |
d00161 | MMSL |
002286 | NDDF |
002287 | NDDF |
4017898 | VANDF |
4017899 | VANDF |
33664007 | SNOMEDCT_US |
372709008 | SNOMEDCT_US |
72469007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9006 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 20 sections |
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9503 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 20 sections |
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9503 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 20 sections |
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1050 | TABLET | 250 mg | ORAL | ANDA | 19 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6663 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6663 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-567 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-331 | CAPSULE, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 21 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-120 | CAPSULE, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 11 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-287 | TABLET | 125 mg | ORAL | ANDA | 18 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-287 | TABLET | 125 mg | ORAL | ANDA | 18 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-288 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-288 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-313 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 16 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-787 | CAPSULE, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 12 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29033-030 | CAPSULE, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 22 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0190 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 13 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-089 | TABLET | 125 mg | ORAL | ANDA | 18 sections |
acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-090 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-103 | TABLET | 250 mg | ORAL | ANDA | 19 sections |
ACETAZOLAMIDE EXTENDED-RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-243 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
ACETAZOLAMIDE EXTENDED-RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-243 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Acetazolamide | Human Prescription Drug Label | 1 | 46708-349 | CAPSULE, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 21 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0577 | TABLET | 125 mg | ORAL | ANDA | 19 sections |
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3003 | TABLET | 250 mg | ORAL | ANDA | 19 sections |
AcetaZOLAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3003 | TABLET | 250 mg | ORAL | ANDA | 19 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3132 | CAPSULE, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 11 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4511 | TABLET | 125 mg | ORAL | ANDA | 18 sections |
Acetazolamide | Human Prescription Drug Label | 1 | 50090-5217 | TABLET | 125 mg | ORAL | ANDA | 18 sections |
Acetazolamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5593 | TABLET | 250 mg | ORAL | ANDA | 17 sections |